Generic Drugs Don’t Come Cheap: Teva Buys Barr For $7.46 Billion

Teva's $7.46 billion acquisition of Barr will create an unrivaled generics powerhouse and position the company as a leader in the industry's next untapped frontier: biosimilars

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet